|
SYAP1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.22550000048305E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.94499999994768E-06 |
| Normal-vs-Stage2 |
1.115010E-01 |
| Normal-vs-Stage3 |
4.09360000008796E-07 |
| Normal-vs-Stage4 |
1.23790000472468E-08 |
| Stage1-vs-Stage2 |
1.141250E-01 |
| Stage1-vs-Stage3 |
1.194650E-01 |
| Stage1-vs-Stage4 |
3.400000E-03 |
| Stage2-vs-Stage3 |
2.252100E-02 |
| Stage2-vs-Stage4 |
1.398100E-03 |
| Stage3-vs-Stage4 |
1.279790E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.13200000040337E-07 |
| Normal-vs-AfricanAmerican |
3.876200E-02 |
| Normal-vs-Asian |
1.236940E-04 |
| Caucasian-vs-AfricanAmerican |
1.845410E-01 |
| Caucasian-vs-Asian |
8.186000E-01 |
| AfricanAmerican-vs-Asian |
2.962000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.55111512312578E-16 |
| Normal-vs-Female |
5.449100E-04 |
| Male-vs-Female |
1.62447832963153E-12 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.16899999999831E-06 |
| Normal-vs-Age(41-60Yrs) |
1.64905999999743E-05 |
| Normal-vs-Age(61-80Yrs) |
1.9685000000047E-06 |
| Normal-vs-Age(81-100Yrs) |
1.629680E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.136000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.829200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.932200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.999400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.765000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.174800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.992100E-02 |
| Classical-VS-Follicular |
2.592800E-01 |
| Classical-VS-Other |
7.860300E-02 |
| Classical-VS-Normal |
2.36109999995904E-06 |
| Tall-VS-Follicular |
2.501900E-02 |
| Tall-VS-Other |
2.150200E-01 |
| Tall-VS-Normal |
4.37750000004122E-06 |
| Follicular-VS-Other |
6.210000E-02 |
| Follicular-VS-Normal |
3.743300E-03 |
| Other-VS-Normal |
5.385000E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.80110000000445E-05 |
| Normal-vs-N1 |
2.46130000047806E-07 |
| N0-vs-N1 |
3.703500E-02 |
|
|
